Immuno-hormonal regulation of tumor proliferation in breast cancer patients
- 作者: Glushkov A.N.1, Polenok E.G.1, Gordeeva L.A.1, Antonov A.V.2, Bayramov P.V.2, Verzhbitskaya N.E.2, Kolpinskiy G.I.3,4
-
隶属关系:
- Federal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of Sciences
- Kuzbass Clinical Oncology Dispensary
- Kemerovo State Medical University
- Kemerovo Clinical Diagnostic Сenter
- 期: 卷 27, 编号 1 (2024)
- 页面: 33-48
- 栏目: ORIGINAL ARTICLES
- URL: https://ogarev-online.ru/1028-7221/article/view/263654
- DOI: https://doi.org/10.46235/1028-7221-13990-IHR
- ID: 263654
如何引用文章
全文:
详细
It is well known that tumor cells proliferation is regulated by sex steroid hormones, estradiol and progesterone (E2 and Pg) in breast cancer patients (BCP). Moreover, specific auto-antibodies to estrogen receptor (ERα) were detected in blood serum of BCP. Their levels positively correlated with the percentage of Ki-67 expressing breast cancer cells. We proposed that antiidiotypic auto-antibodies to E2 and Pg (IgG2-E2 and IgG2-Pg) could act as antibodies against membrane ER and progesterone receptor (PR). Our study aimed for research of IgG2-E2 and IgG2-Pg according to E2 and Pg serum levels in association with Ki-67 positive tumors in BCP. Antiidiotypic antibodies were studied in ER-positive patients with breast cancer (stage I, n = 374, and stage II-IV, n = 379,) using ELISA technique with monoclonal antibodies against E2 and Pg as adsorbed antigens. Blood serum concentrations of E2 and Pg were measured using “ImmunoEA-Estradiol” and “ImmunoEA-Progesterone” test-systems (“Immunotech”, Russia). Tumor Ki-67 was studied by standard immunohistochemical technique at the Kemerovo Oncological Hospital. Higher percentage of Ki-67 positive breast cancer cells (Ki-67 > 30) was increased in BCP II-IV stages compared with stage I patients (50.7% vs 29.8%, p < 0,001). Such increased values were detected for the BCP with low levels of both IgG2-E2 and IgG2-Pg antibodies in the following subgroups: 1) at low serum E2 concentration of ≤ 200 pmol/L (50.9% vs 21.3%, р < 0.001); 2) at the E2 exceeding 200 pmol/L (74.2% vs 34.1%, р = 0.003); 3) at the Pg levels under 600 pmol/L (60.6% vs 22.2%, р < 0.001); 4) at Pg values exceeding 600 pmol/L (58.5% vs 30.8%, р = 0.02). Similar differences were not revealed between stage II-IV and stage I BCP with low levels of both IgG2-E2 and IgG2-Pg. Corresponding Ki-67 > 30 indices were as follows: 1) 36.9% vs 22.0% (р = 0.14); 2) 48.4% vs 34.5% (р = 0.08); 3) 34.0% vs 27.7% (р = 0.75). Significant differences were detected in BCP with Pg > 600 pmol/L and high IgG2-E2 and IgG2-Pg levels only: 48.1% vs 26.6%, (р = 0.01). Hence, antiidiotypic auto-antibodies to steroid hormones may participate in regulation of tumor proliferation in BCP. Immunoassay of IgG2-E2 and IgG2-Pg may be used for prognosis of tumor proliferation upon breast cancer progression.
作者简介
A. Glushkov
Federal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of Sciences
Email: glushkovan@ihe.sbras.ru
ORCID iD: 0000-0002-8560-6719
SPIN 代码: 9536-8530
Scopus 作者 ID: 7006323832
Researcher ID: Q-5985-2016
PhD, MD (Medicine), Professor, Chief Research Associate, Immunogenetics Laboratory, Institute of Human Ecology
俄罗斯联邦, KemerovoE. Polenok
Federal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of Sciences
Email: egpolenok@mail.ru
ORCID iD: 0000-0002-9368-2340
SPIN 代码: 3925-0185
Scopus 作者 ID: 6506567994
Researcher ID: Q-5381-2016
PhD (Pharmacy), Leading Research Associate, Immunochemistry Laboratory, Institute of Human Ecology
俄罗斯联邦, KemerovoL. Gordeeva
Federal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of Sciences
Email: gorsib@rambler.ru
ORCID iD: 0000-0001-5870-7584
SPIN 代码: 6662-4616
Scopus 作者 ID: 14052058500
Researcher ID: R-2781-2016
PhD (Biology), Leading Research Associate, Immunogenetics Laboratory, Institute of Human Ecology
俄罗斯联邦, KemerovoA. Antonov
Kuzbass Clinical Oncology Dispensary
Email: al0412@mail.ru
ORCID iD: 0000-0003-0802-9759
Chief, Breast Cancer Department
俄罗斯联邦, KemerovoP. Bayramov
Kuzbass Clinical Oncology Dispensary
Email: bayramov_pavel82@mail.ru
ORCID iD: 0000-0002-4649-5892
Main Physician, Pathology Department
俄罗斯联邦, KemerovoN. Verzhbitskaya
Kuzbass Clinical Oncology Dispensary
Email: verzhbitskaia@mail.ru
ORCID iD: 0000-0003-3860-825X
PhD (Medicine), Pathologist, Pathology Department
俄罗斯联邦, KemerovoG. Kolpinskiy
Kemerovo State Medical University; Kemerovo Clinical Diagnostic Сenter
编辑信件的主要联系方式.
Email: Glebss@mail.ru
ORCID iD: 0000-0002-5526-2687
SPIN 代码: 6894-6419
Scopus 作者 ID: 56677706300
PhD, MD (Medicine), Professor, Department of Radiology, Radiotherapy and Oncology, Kemerovo State Medical University; Main Physician, Kemerovo Clinical Diagnostic Сenter
俄罗斯联邦, Kemerovo; Kemerovo参考
- Глушков А.Н., Поленок Е.Г., Гордеева Л.А., Мун С.А., Костянко М.В., Колпинский Г.И., Вафин И.А., Антонов А.В., Вержбицкая Н.Е. Иммунные реакции на химические канцерогены и стероидные гормоны у больных с доброкачественными и злокачественными опухолями молочной железы // Российский иммунологический журнал, 2021. Т. 24, № 1. С. 101-108. [Glushkov A.N., Polenok E.G., Gordeeva L.A., Mun S.A., Kostyanko M.V., Kolpinckiy G.I., Vafin I.A., Antonov A.V., Verzhbitskaja N.E. Immune reactions to clinical carcinogens and steroid hormones in breast pre-cancer and cancer patients. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2021, Vol. 24, no. 1, pp. 101-108. (In Russ.)] doi: 10.46235/1028-7221-977-IRT.
- Глушков А.Н., Поленок Е.Г., Мун С.А., Гордеева Л.А., Костянко М.В., Антонов А.В., Байрамов П.В., Вержбицкая Н.Е., Колпинский Г.И. Кооперативное участие стероидных гормонов и гормон-специфических аутоантител в прогрессии рака молочной железы // Фундаментальная и клиническая медицина, 2023. Т. 8, № 2. С. 19-32. [Glushkov A.N., Polenok E.G., Gordeeva L.A., Mun S.A., Kostyanko M.V., Antonov A.V., Verzhbitskaya N.N., Bayramov P.V., Verzhbitskaya N.E., Kolpinskiy G.I. Cooperation of steroid hormones and hormone-specific autoantibodies in breast cancer progression. Fundamentalnaya i klinicheskaya meditsina = Fundamental and Clinical Medicine, 2023, Vol. 8, no. 2, pp. 19-32. (In Russ.)].
- Поленок Е.Г., Гордеева Л.А., Мун С.А., Костянко М.В., Антонов А.В., Вержбицкая Н.Е., Байрамов П.В., Колпинский Г.И., Вафин И.А., Глушков А.Н. Кооперативное участие идиотипических и антиидиотипических антител в стероид-зависимом химическом канцерогенезе // Российский иммунологический журнал, 2023. Т. 25, № 1. С. 35-48. [Polenok E.G., Gordeeva L.A., Mun S.A., Kostyanko M.V., Antonov A.V., Verzhbitskaya N.E., Bairamov P.V., Kolpinskiy G.I.,Vafin I.A., Glushkov A.N. Cooperation of idiotypic and anti-idiotypic antibodies at the steroid-depended chemical carcinogenesis. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2023, Vol. 25, no. 1, pp. 35-48. (In Russ.)] doi: 10.46235/1028-7221-1177-CO.
- Chaudhri R.A., Schwartz N., Elbaradie K., Schwartz Z., Boyan B.D. Role of ERα 36 in membrane-associated signaling by estrogen. Steroids, 2014, Vol. 81, pp. 74-80.
- Dressing G.E., Goldberg J.E., Charles N.J., Schwertfeger K.L., Lange C.A. Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications. Steroids, 2011, Vol. 76, no. 1-2, pp. 11-17.
- Greiner M., Pfeiffer D., Smith R.D. Principles and practical application of the receiver operating characteristic analysis for diagnostic test. Prev. Vet. Med., 2000, Vol. 45, pp. 23-41.
- Kampa M., Notas G., Pelekanou V., Troullinaki M., Andrianaki M., Azariadis K., Kampouri E., Lavrentaki K., Castanas E. Early membrane initiated transcriptional effects of estrogens in breast cancer cells: First pharmacological evidence for a novel membrane estrogen receptor element (ERx). Steroids, 2012, Vol. 77, no. 10, pp. 959-967.
- Li Q., Gao H., Yang H., Wei W., Jiang Y. Estradiol promotes the progression of ER+ breast cancer through methylation-mediated RSK4 inactivation. Onco Targets Ther., 2019, Vol. 12, pp. 5907-5916.
- Luconi M., Francavilla F., Porazzi I., Macerola B., Forti G., Baldi E. Human spermatozoa as a model for studying membrane receptors mediating rapid nongenomic effects of progesterone and estrogens. Steroids, 2004, Vol. 69, no. 8-9, pp. 553-559.
- Maselli A., Capoccia S., Pugliese P., Raggi C., Cirulli F., Fabi A., Malorni W., Pierdominici M., Ortona E. Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their level correlate with breast cancer cell proliferation. Oncoimmunology, 2016, Vol. 5, no. 2, e1074375. doi: 10.1080/2162402X.2015.1074375.
- Mohammed H., Russell I.A., Stark R., Rueda O.M., Hickey T.E., Tarulli G.A., Serandour A.A., Birrell S.N., Bruna A., Saadi A., Menon S., Hadfield J., Pugh M., Raj G.V., Brown G.D., D’Santos C., Robinson J.L., Silva G., Launchbury R., Perou C.M., Stingl J., Caldas C., Tilley W.D., Carroll J.S. Progesterone receptor modulates ERα action in breast cancer. Nature, 2015, Vol. 523, no. 7560, pp. 313-317.
- Norfleet A.M., Clarke C.H., Gametchu B., Watson C.S. Antibodies to the estrogen receptor-alpha modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors. FASEB J., 2000, Vol. 14, no. 1, pp. 157-165.
- Sömjen D., Kohen F., Lieberherr M. Nongenomic effects of an anti-idiotypic antibody as an estrogen mimetic in female human and rat osteoblasts. J. Cell. Biochem., 1997, Vol. 65, no. 1, pp. 53-66.
补充文件
